Typhoid Fever Vaccines Market Forecast and Growth 2031

The Typhoid Fever VaccinesMarket was valued at US$ 376.76 million in 2021 and is expected to reach US$ 651.87 million by 2031. The market is expected to register a CAGR of 7.1% from 2023–2031. Penetration of combination typhoid vaccines is likely to remain key Typhoid Fever Vaccines Market trends.

Typhoid Fever VaccinesMarket Analysis

Rising Incidence and Mortality of Typhoid Accelerate Demand for Typhoid Conjugate Vaccines

According to the World Health Organization (WHO) March 2023 report, in 2019, an estimated 9 million people got sick due to typhoid fever, and 110,000 people die due to typhoid fever annually. Also, travellers are at high risk of developing typhoid fever, particularly in Asia and Sub-Saharan Africa. Therefore, with rising incidence and mortality cases, demand for typhoid vaccines is all-time high. For example, the WHO advises countries to adopt immunization by Typhoid Conjugate Vaccines (TCV) to control the disease in endemic regions. The TCV is the first typhoid vaccine suitable for children from six months of age and is the most preferred typhoid vaccine choice globally. The Global Vaccine Market Model (GVMM) estimated that the total market revenues for TCV in middle-income countries (MICs) and Low-Income Countries (LICs) are estimated to reach US$ 44 million, only representing a market share of approx—14%. 

Source: GVMM

Further, the United Nations Children's Fund (UNICEF) holds more than 95% TCV vaccine market share particularly in Sub-Saharan Africa and South and Southeast Asia for LICs and MICs. The proper supply of TCV vaccines in Sub-Saharan Africa and South and Southeast Asia  is done by UNICEF to reduce the high-burden typhoid fever cases among population.  Therefore, rising prevalence and mortality associated due to typhoid fever proper demand and supply of typhoid vaccines to epidemic countries are the influencing factors responsible for typhoid fever vaccines market growth during 2021-2031.

Typhoid Fever VaccinesMarket Overview

Government intervention and smart vaccine delivery solutions continue to influence typhoid fever vaccines significantly. Government support for the typhoid immunization and rising incidence and mortality of typhoid are the most influential factors responsible for Typhoid Fever Vaccines Market growth. Combination typhoid vaccines is a key trend for Typhoid Fever Vaccines Market growth. Preclinical studies for developing trivalent typhoid/non-typhoidal salmonella glycoconjugate vaccine will provide lucrative market opportunity.

Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Get FREE CUSTOMIZATION

Typhoid Fever Vaccines Market: Strategic Insights

• Get Top Key Market Trends of this report.
  This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Free Sample PDF

Typhoid Fever VaccinesMarket Drivers and Opportunities

Government Support for the Typhoid Immunization to Favor Market

Government support for typhoid immunization accelerates the demand for vaccines globally. For example, the Commonwealth of Australia report reveals that children aged less than 2 and adults are recommended to receive typhoid vaccine if they are traveling to epidemic regions such as Sub-Saharan Africa and South and Southeast Asia. Also, children aged less than 2 and adults can receive 1 dose of parenteral typhoid vaccine, and children above 6 years of age and adults can receive 3 or 4 doses of oral typhoid vaccine.

Further, in Canada, typhoid vaccination is mandatory for travellers over 2 years of age who travel to South Asia, including Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, and Sri Lanka. Therefore, government support for typhoid immunization program will contribute more for the typhoid fever vaccines market to grow exponentially during 2021-2031.

Preclinical Studies for Developing Trivalent Typhoid/Non-Typhoidal Salmonella Glycoconjugate Vaccine– An Opportunity

In February 2024, SK Bioscience and the International Vaccine Institute (IVI) announced that the typhoid conjugate vaccine developed by SK Bioscience achieved the WHO prequalification (PQ) for public procurement of the vaccine by the UN organizations resulting a boost for the global TCV supply. The Phase 2 clinical trial results of the "SKYTYPHOID" booster shot reveal that the two doses of the TCV in infants aged 6 to 23 months developed a strong immune response.

Additionally, several manufacturers are developing TCVs that are in the preclinical stage. For example, manufacturers are developing a trivalent typhoid/non-typhoidal Salmonella glycoconjugate vaccine particularly for population in Sub-Saharan Africa. Also, a multiple antigen presenting system (MAPS)--based typhoid and paratyphoid A vaccine development is still at the preclinical stage and is a promising alternative to the traditional conjugate vaccine. Therefore, clinical studies to develop innovative typhoid vaccine will provide lucrative market opportunities for the manufacturers ultimately driving Typhoid Fever Vaccinesmarket.

Typhoid Fever Vaccines

Market Report Segmentation Analysis

Key segments that contributed to the derivation of the Typhoid Fever Vaccines Market analysis are candidature and services.

• Based on Vaccine Type, the Typhoid Fever Vaccines Market is segmented into live attenuated vaccine, capsular polysaccharide vaccines, conjugate vaccine, others. The capsular polysaccharide vaccines may hold a larger market share in 2023.
• Based on Route of Administration, the Typhoid Fever Vaccines Market is bifurcated into oral and injectable. The injectable segment may hold a larger market share in 2023.

Typhoid Fever Vaccines Market Share Analysis by Geography

The geographic scope of the Typhoid Fever VaccinesMarket report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South America/South & Central America.

North America has dominated the Typhoid Fever Vaccines Market. In North America, US accounts considerable share for typhoid fever vaccines. North America represents the largest typhoid vaccine market share and revenue due to rising healthcare expenditure and development of innovative vaccines through clinical trials are the most influential factors responsible for market growth. Asia Pacific is anticipated to grow with the highest CAGR in the coming years.  

Typhoid Fever Vaccines

Market Report Scope

Typhoid Fever Vaccines Market Regional Insights

The regional trends and factors influencing the Typhoid Fever Vaccines Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Typhoid Fever Vaccines Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

Typhoid Fever Vaccines Market Market Report Scope

Market Players Density: Understanding Its Impact on Business Dynamics

The Typhoid Fever Vaccines Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.

Major Companies operating in the Typhoid Fever Vaccines Market are:

1. Indian Immunologicals
2. LBIP
3. Finlay
4. Incepta
5. Panacea
6. Bharat Biotech

Disclaimer: The companies listed above are not ranked in any particular order.

Typhoid Fever VaccinesMarket News and Recent Developments

The Typhoid Fever VaccinesMarket is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in them market for Typhoid Fever Vaccines and strategies:

• In November 2023, the Republic of Korea announced a new typhoid vaccine conjugate, "Bio-TCV typhoid conjugate vaccine (TCV)," to be licensed in Indonesia following marketing approval from Badan Pengawas Obat dan Makanan (BPOM), the national regulatory authority. The new vaccine, "Bio-TCV," is a Vi polysaccharide conjugated vaccine.

Typhoid Fever VaccinesMarket Report Coverage and Deliverables

The “Typhoid Fever VaccinesMarket Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

• Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
• Market dynamics such as drivers, restraints, and key opportunities
• Key future trends
• Detailed PEST/Porter’s Five Forces and SWOT analysis
• Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments
• Detailed company profiles